Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
US9439897B2 · kind B2 · utility
4Cited by
15References
29Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 23, 2015 |
| Grant date | Sep 13, 2016 |
| Priority date | — |
| Expiry date | Jan 23, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for the treatment of a cell proliferation disease or disorder in a subject, involving applying a psoralen derivative lacking a DNA cross-linking motif to cancer cells, applying a psoralen or a derivative thereof and lapatinib, or applying a psoralen or derivative thereof and neratinib, to a subject and further applying initiation radiation energy form an energy source.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.